» Articles » PMID: 22381955

Prevalence and Correlates of the Proposed DSM-5 Diagnosis of Chronic Depressive Disorder

Overview
Journal J Affect Disord
Date 2012 Mar 3
PMID 22381955
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The draft proposal to add Chronic Depressive Disorder to DSM-5 will combine DSM-IV Dysthymic Disorder and Major Depressive Disorder, with chronic specifier, into a single diagnosis.

Objective: The objective of this study is to estimate the prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder using unit record data from the 2007 Australian National Survey of Mental Health and Wellbeing.

Design: Secondary analysis of a nationally representative household survey.

Setting: Urban and rural census tracts.

Participants: One individual between the ages of 16 and 85 years from 8841 households was interviewed for the survey.

Main Outcome Measure: Lifetime prevalence estimates for chronic and non-chronic depression were determined using data from the World Health Organization's Composite International Diagnostic Interview, version 3.0 (WMH-CIDI 3.0).

Results: Chronic depression of at least two years' duration had a lifetime prevalence of 4.6% (95% CI: 3.9-5.3%) and was found in 29.4% (95% CI: 25.6-33.3%) of individuals with a lifetime depressive disorder. Higher rates of psychiatric co-morbidity (OR=1.42; 95% CI=1.26-1.61), older age (OR=1.04; 95% CI=1.02-1.05), a younger age of onset (OR=0.97; 95% CI=0.95-0.98) and more frequent episodes of depression (OR=1.75; 95% CI=1.07-2.86) were found to be significant correlates of chronic depression. The first episode of depression for individuals with chronic depression often developed after the death of someone close (OR=2.38; 95% CI 1.16-5.79).

Conclusions: Chronic depression is highly prevalent among community-residing persons and has a set of correlates that discriminate it from non-chronic depression. The distinction between chronic and non-chronic depression proposed for DSM-5, in the form of Chronic Depressive Disorder, seems to be warranted.

Citing Articles

Trajectories of pharmacological therapies for treatment-resistant depression: a longitudinal study.

DiBello J, Xiong X, Liu X, Zhong W, Merola A, Li M BMC Psychiatry. 2025; 25(1):215.

PMID: 40065240 PMC: 11892204. DOI: 10.1186/s12888-025-06518-8.


Efficacy of psychotherapy versus pharmacotherapy, or their combination, in chronic depression: study protocol for a systematic review and network meta-analysis using aggregated and individual patient data.

Schramm E, Elsaesser M, Muller J, Kwarteng N, Evrenoglou T, Cuijpers P BMJ Open. 2025; 15(2):e089356.

PMID: 39971604 PMC: 11840898. DOI: 10.1136/bmjopen-2024-089356.


Antidepressive and anxiolytic effects of a combination of Saffron and Chamomile in rats and their relationship with serotonin using methods.

Amin F, Ahmad S, Wasim M, Khan A, Manzoor Arain F, Batool Z J Tradit Chin Med. 2025; 45(1):49-56.

PMID: 39957158 PMC: 11764942. DOI: 10.19852/j.cnki.jtcm.2025.01.005.


[Long-term courses of major depressive disorder : Characteristics, risk factors and the definitional challenge of treatment response].

Paetow R, Frodl T Nervenarzt. 2024; 96(1):37-45.

PMID: 39400712 PMC: 11772401. DOI: 10.1007/s00115-024-01756-9.


Development and psychometric evaluation of a questionnaire for the assessment of depression in primary care: a cross-sectional study.

Teusen C, Buhner M, Hapfelmeier A, von Schrottenberg V, Linde K, Gensichen J BMJ Open. 2024; 14(7):e084102.

PMID: 39013641 PMC: 11253771. DOI: 10.1136/bmjopen-2024-084102.